Shukla, AkashQi, XiaolongÖrmeci, NecatiDuseja, AjaySarin, Shiv2026-11-052026-11-052026Shukla, A., Qi, X., Örmeci, N., Duseja, A., & Sarin, S. (2026). A survey on terminology and diagnostic features of a subgroup of non-cirrhotic portal hypertension patients: A report from asia-pacific experts. Journal of Clinical and Experimental Hepatology, 17(1), pp. 1-6. https://doi.org/10.1016/j.jceh.2026.1036712213-34530973-6883https://doi.org/10.1016/j.jceh.2026.103671https://hdl.handle.net/20.500.13055/1692Background: There have been recent proposals to replace non-cirrhotic portal fibrosis (NCPF), idiopathic portal hypertension (IPH), idiopathic non-cirrhotic portal hypertension, nodular regenerative hyperplasia, etc. with an all-encompassing term “porto-sinusoidal vascular disorder.” However, the Asia-Pacific Association for Study of the Liver recommended continued use of the term NCPF/IPH. Methods: We sent this questionnairebased online survey to capture the clinical perspectives of 300 specialized experts in the Asia-Pacific region with complete anonymisation. Results: The survey (n = 242 respondents) revealed overwhelming support for the continued use of the NCPF/IPH nomenclature, with 93.4% of experts favoring the term in daily practice. Furthermore, 80.1% endorsed liver histopathology as a fundamental diagnostic component, while 95.9% agreed that a lower-than-cirrhosis-range liver stiffness measurement obtained via transient elastography in the presence of portal hypertension is highly indicative of the condition.A total of 91% agreed with the APASL staging system. Conclusions: The results highlight a persistent regional consensus favoring a clinical, histological and portal hypertension–driven diagnostic and staging framework for NCPF. The survey reveals strong support for the continued use of the NCPF/IPH nomenclature. ( J CLIN EXP HEPATOL 2027;17:103671)eninfo:eu-repo/semantics/closedAccessPortal HypertensionPortal Sinusoidal Vascular DisorderVascular Liver DisordersNon-Cirrhotic Portal HypertensionNodular Regenerative HyperplasiaObliterative Portal VenopathyArticle10.1016/j.jceh.2026.10367117116Q2WOS:0019017695000012-s2.0-105052582096PMID: 42893017Q2